Other studies demonstrated that Wnt5a could enhance migration of breast-cancer cells.13,14 In this study, we found that Wnt5a enhances the migration of serum-starved breast-cancer PDX cells that expressed ROR1, and that such effects could also be blocked by cirmtuzumab (Fig. 2g). Here, ROR1 is linked to breast cancer.